Common use of Royalty Reports and Payments Clause in Contracts

Royalty Reports and Payments. Within [...***...] following the end of each calendar quarter following the First Commercial Sale of a Licensed Product anywhere in the Territory, Lumena shall provide Sanofi with a report containing the following information for the applicable calendar quarter, on a Licensed Product-by-Licensed Product and country-by-country basis: (i) the amount of gross sales of such Licensed Product in such country, (ii) an itemized calculation of Net Sales in such country showing deductions provided for in the definition of Net Sales in Section 1.31, (iii) a calculation of the royalty payment due on such sales, (iv) an accounting of the number of units and prices for Licensed Product sold, (v) the exchange rate for such country (as published in The Wall Street Journal, Eastern Edition, on the last business day of the last month in the calendar quarter to which such payments relate), and (vi) the date of First Commercial Sale of such Licensed Product in such country. Concurrent with the delivery of the applicable quarterly report, Lumena shall pay all amounts due to Sanofi pursuant to this Section 3.5 with respect to Net Sales by Lumena, its Affiliates and their respective sublicensees and subcontractors for such calendar quarter.

Royalty Reports and Payments. Within [...…***...…] following the end of each calendar quarter following the First Commercial Sale of a Licensed Product anywhere in the Territory, Lumena Mirum shall provide Sanofi Shire with a report containing the following information for the applicable calendar quarter, on a Licensed Product-by-Licensed Product and country-by-country basis: (i) the amount of gross sales of such Licensed Product in such country, (ii) an itemized calculation of Net Sales in such country showing deductions provided for in the definition of Net Sales in Section 1.311.37, (iii) a calculation of the royalty payment due on such sales, (iv) an accounting of the number of units and prices for Licensed Product sold, (v) the exchange rate for such country (as published in The Wall Street Journal, Eastern Edition, on the last business day of the last month in the calendar quarter pursuant to which such payments relateSection 4.6), and (vi) the date of First Commercial Sale of such Licensed Product in such country, and (vii) identification of whether such Licensed Product is an SHP625 Licensed Product or an SHP626 Licensed Product. Concurrent with the delivery of the applicable quarterly report, Lumena Mirum shall pay all amounts due to Sanofi Shire pursuant to this Section 3.5 4.5 with respect to Net Sales by LumenaMirum, any of its Affiliates and their respective sublicensees and subcontractors for such calendar quarter.

Royalty Reports and Payments. Within [...…***...…] following the end of each calendar quarter following the First Commercial Sale of a Licensed Product anywhere in the Territory, Lumena shall provide Sanofi with a report containing the following information for the applicable calendar quarter, on a Licensed Product-by-Licensed Product and country-by-country basis: (i) the amount of gross sales of such Licensed Product in such country, (ii) an itemized calculation of Net Sales in such country showing deductions provided for in the definition of Net Sales in Section 1.31, (iii) a calculation of the royalty payment due on such sales, (iv) an accounting of the number of units and prices for Licensed Product sold, (v) the exchange rate for such country (as published in The Wall Street Journal, Eastern Edition, on the last business day of the last month in the calendar quarter to which such payments relate), and (vi) the date of First Commercial Sale of such Licensed Product in such country. Concurrent with the delivery of the applicable quarterly report, Lumena shall pay all amounts due to Sanofi pursuant to this Section 3.5 with respect to Net Sales by Lumena, its Affiliates and their respective sublicensees and subcontractors for such calendar quarter.

Royalty Reports and Payments. Within [...***...[ * ] following the end of each calendar quarter, commencing with the calendar quarter following in which the First Commercial Sale of a Licensed Product is made anywhere in the Territoryworld, Lumena Bayer shall provide Sanofi Onyx a report estimating Net Sales of the Product for such calendar quarter. Within [ * ] following the end of each calendar quarter, commencing with the calendar quarter in which the First Commercial Sale of the Product is made anywhere in the world, Bayer shall provide Onyx with a report containing the following information for the applicable such calendar quarter, on a Licensed Product-by-Licensed Product and country-by-country basis: (i) the amount of gross sales of such Licensed Product in such country, (ii) an itemized calculation of Net Sales in such country showing deductions provided for in the definition of “Net Sales in Section 1.31, Sales,” (iii) a the conversion of such Net Sales from the currency of sale into Dollars, and (iv) the calculation of the royalty payment due on such sales, (iv) an accounting of the number of units and prices for Licensed Product sold, (v) the exchange rate for such country (as published in The Wall Street Journal, Eastern Edition, on the last business day of the last month in the calendar quarter sales pursuant to which such payments relate), and (vi) the date of First Commercial Sale of such Licensed Product in such countrySection 4.1. 1. Concurrent with the delivery of the applicable quarterly report, Lumena Bayer shall pay to Onyx in Dollars all amounts due to Sanofi Onyx pursuant to this Section 3.5 4.1 with respect to Net Sales by LumenaBayer, its Affiliates and their respective licensees and sublicensees and subcontractors for such within [ * ] following the end of each calendar quarterquarter in which royalties are due under Section 4.1.1.